C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib
Lenvatinib has become a first line treatment for unresectable hepatocellular carcinoma (HCC). However, continued administration is impossible in many patients due to treatment resistance and severe adverse events. This study aimed to identify predicting factors to select patients likely to benefit f...
Gespeichert in:
| Veröffentlicht in: | PloS one 2020-12, Vol.15 (12), p.e0244370 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 12 |
| container_start_page | e0244370 |
| container_title | PloS one |
| container_volume | 15 |
| creator | Hayashi, Tsuguru Shibata, Michihiko Oe, Shinji Miyagawa, Koichiro Honma, Yuichi Harada, Masaru |
| description | Lenvatinib has become a first line treatment for unresectable hepatocellular carcinoma (HCC). However, continued administration is impossible in many patients due to treatment resistance and severe adverse events. This study aimed to identify predicting factors to select patients likely to benefit from lenvatinib treatment.
We retrospectively analyzed 53 patients who were treated with lenvatinib for unresectable HCC. They were divided to two groups; low C-reactive protein (CRP) group with pretreatment serum CRP level < 1.0 mg/dL and high CRP group with serum CRP level ≥ 1.0 mg/dl. Overall survival (OS), total amount administered, and period of treatment were compared between the two groups.
The high CRP group showed a significantly poorer OS than the low CRP group (0.0% vs 71.5%/ 1year, p < 0.01). Multivariate analyses revealed that high CRP was a significant negative factor for OS (HR: 7.69, 95% confidence interval: 2.43-24.3, p < 0.001), and this result was independent of Child-Pugh score and existing tumor factors. Relative dose intensity at 8 weeks was lower (p = 0.01) and time to treatment failure was shorter (P < 0.001) in the high CRP group.
CRP level was associated with OS in HCC patients treated with lenvatinib. CRP could be a useful marker to identify patients most likely to benefit from lenvatinib treatment. |
| doi_str_mv | 10.1371/journal.pone.0244370 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_pubmed_primary_33351844</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A646267524</galeid><doaj_id>oai_doaj_org_article_e596539edf7547bcbf5e2dc5d3bd171d</doaj_id><sourcerecordid>A646267524</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-dcf2ee121e01d6eee5ef77d5cac35cac04f29d6441efef43d41b9368ec238d793</originalsourceid><addsrcrecordid>eNqNkm2L1DAUhYso7rr6D0QDgiA4Y_PSZPpFWAZ1BxYWfPsa0uR2JksnmU3S6oI_3ozTXaagIIHmkj7nNJyeoniOyzmmAr-79n1wqpvvvIN5SRijonxQnOKakhknJX14NJ8UT2K8LsuKLjh_XJxQSiu8YOy0-LWcBVA62QHQLvgE1iGtXJ7BWJ2Q8RGQdQlctOn2LUp2Cyh5lLIqbcEl1Crb9QGQcgb5AYLqOhT7MNhBdVmJLpbLAw0G_bBpgzpwg0rW2eZp8ahVXYRn435WfPv44evyYnZ59Wm1PL-caV6TNDO6JQCYYCix4QBQQSuEqbTSdP8oWUtqwxnD0ELLqGG4qSlfgCZ0YURNz4qXB99d56Mcg4uSMEHKhaCUZ2J1IIxX13IX7FaFW-mVlX8OfFhLFZLVHUioal7RGkwrKiYa3bQVEKMrQxuDBTbZ6_34tb7ZgtE5pBzKxHT6xtmNXPtBClHlv0KywavRIPibHmL6x5VHaq3yraxrfTbTWxu1POeMEy4qwjI1_wuVl4Gt1bk6rc3nE8GbiSAzCX6mtepjlKsvn_-fvfo-ZV8fsRtQXdpE3_XJehenIDuAOvgYA7T3yeFS7pt_l4bcN1-Ozc-yF8ep34vuqk5_AzzcAV4</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2472087336</pqid></control><display><type>article</type><title>C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Public Library of Science (PLoS)</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Hayashi, Tsuguru ; Shibata, Michihiko ; Oe, Shinji ; Miyagawa, Koichiro ; Honma, Yuichi ; Harada, Masaru</creator><contributor>Huang, Yi-Hsiang</contributor><creatorcontrib>Hayashi, Tsuguru ; Shibata, Michihiko ; Oe, Shinji ; Miyagawa, Koichiro ; Honma, Yuichi ; Harada, Masaru ; Huang, Yi-Hsiang</creatorcontrib><description>Lenvatinib has become a first line treatment for unresectable hepatocellular carcinoma (HCC). However, continued administration is impossible in many patients due to treatment resistance and severe adverse events. This study aimed to identify predicting factors to select patients likely to benefit from lenvatinib treatment.
We retrospectively analyzed 53 patients who were treated with lenvatinib for unresectable HCC. They were divided to two groups; low C-reactive protein (CRP) group with pretreatment serum CRP level < 1.0 mg/dL and high CRP group with serum CRP level ≥ 1.0 mg/dl. Overall survival (OS), total amount administered, and period of treatment were compared between the two groups.
The high CRP group showed a significantly poorer OS than the low CRP group (0.0% vs 71.5%/ 1year, p < 0.01). Multivariate analyses revealed that high CRP was a significant negative factor for OS (HR: 7.69, 95% confidence interval: 2.43-24.3, p < 0.001), and this result was independent of Child-Pugh score and existing tumor factors. Relative dose intensity at 8 weeks was lower (p = 0.01) and time to treatment failure was shorter (P < 0.001) in the high CRP group.
CRP level was associated with OS in HCC patients treated with lenvatinib. CRP could be a useful marker to identify patients most likely to benefit from lenvatinib treatment.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0244370</identifier><identifier>PMID: 33351844</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Ablation ; Aged ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - therapeutic use ; Biology and Life Sciences ; Biomarkers, Tumor - blood ; C-reactive protein ; C-Reactive Protein - metabolism ; Cancer therapies ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - metabolism ; Confidence intervals ; Drug dosages ; Drug therapy ; Environmental health ; Female ; Hepatocellular carcinoma ; Hepatoma ; Humans ; Internal medicine ; Liver cancer ; Liver Neoplasms - drug therapy ; Liver Neoplasms - metabolism ; Male ; Medical prognosis ; Medical records ; Medicine ; Medicine and Health Sciences ; Multivariate Analysis ; Patient outcomes ; Phenylurea Compounds - administration & dosage ; Phenylurea Compounds - therapeutic use ; Physical Sciences ; Physiological aspects ; Proteins ; Quinolines - administration & dosage ; Quinolines - therapeutic use ; Research and Analysis Methods ; Retrospective Studies ; Survival ; Survival Analysis ; Time-to-Treatment ; Treatment Failure ; Treatment resistance</subject><ispartof>PloS one, 2020-12, Vol.15 (12), p.e0244370</ispartof><rights>COPYRIGHT 2020 Public Library of Science</rights><rights>2020 Hayashi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Hayashi et al 2020 Hayashi et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-dcf2ee121e01d6eee5ef77d5cac35cac04f29d6441efef43d41b9368ec238d793</citedby><cites>FETCH-LOGICAL-c692t-dcf2ee121e01d6eee5ef77d5cac35cac04f29d6441efef43d41b9368ec238d793</cites><orcidid>0000-0002-3312-1672</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755182/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755182/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,2096,2915,23847,27905,27906,53772,53774,79349,79350</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33351844$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Huang, Yi-Hsiang</contributor><creatorcontrib>Hayashi, Tsuguru</creatorcontrib><creatorcontrib>Shibata, Michihiko</creatorcontrib><creatorcontrib>Oe, Shinji</creatorcontrib><creatorcontrib>Miyagawa, Koichiro</creatorcontrib><creatorcontrib>Honma, Yuichi</creatorcontrib><creatorcontrib>Harada, Masaru</creatorcontrib><title>C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Lenvatinib has become a first line treatment for unresectable hepatocellular carcinoma (HCC). However, continued administration is impossible in many patients due to treatment resistance and severe adverse events. This study aimed to identify predicting factors to select patients likely to benefit from lenvatinib treatment.
We retrospectively analyzed 53 patients who were treated with lenvatinib for unresectable HCC. They were divided to two groups; low C-reactive protein (CRP) group with pretreatment serum CRP level < 1.0 mg/dL and high CRP group with serum CRP level ≥ 1.0 mg/dl. Overall survival (OS), total amount administered, and period of treatment were compared between the two groups.
The high CRP group showed a significantly poorer OS than the low CRP group (0.0% vs 71.5%/ 1year, p < 0.01). Multivariate analyses revealed that high CRP was a significant negative factor for OS (HR: 7.69, 95% confidence interval: 2.43-24.3, p < 0.001), and this result was independent of Child-Pugh score and existing tumor factors. Relative dose intensity at 8 weeks was lower (p = 0.01) and time to treatment failure was shorter (P < 0.001) in the high CRP group.
CRP level was associated with OS in HCC patients treated with lenvatinib. CRP could be a useful marker to identify patients most likely to benefit from lenvatinib treatment.</description><subject>Ablation</subject><subject>Aged</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biology and Life Sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>C-reactive protein</subject><subject>C-Reactive Protein - metabolism</subject><subject>Cancer therapies</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - metabolism</subject><subject>Confidence intervals</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Environmental health</subject><subject>Female</subject><subject>Hepatocellular carcinoma</subject><subject>Hepatoma</subject><subject>Humans</subject><subject>Internal medicine</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - metabolism</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical records</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Multivariate Analysis</subject><subject>Patient outcomes</subject><subject>Phenylurea Compounds - administration & dosage</subject><subject>Phenylurea Compounds - therapeutic use</subject><subject>Physical Sciences</subject><subject>Physiological aspects</subject><subject>Proteins</subject><subject>Quinolines - administration & dosage</subject><subject>Quinolines - therapeutic use</subject><subject>Research and Analysis Methods</subject><subject>Retrospective Studies</subject><subject>Survival</subject><subject>Survival Analysis</subject><subject>Time-to-Treatment</subject><subject>Treatment Failure</subject><subject>Treatment resistance</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNkm2L1DAUhYso7rr6D0QDgiA4Y_PSZPpFWAZ1BxYWfPsa0uR2JksnmU3S6oI_3ozTXaagIIHmkj7nNJyeoniOyzmmAr-79n1wqpvvvIN5SRijonxQnOKakhknJX14NJ8UT2K8LsuKLjh_XJxQSiu8YOy0-LWcBVA62QHQLvgE1iGtXJ7BWJ2Q8RGQdQlctOn2LUp2Cyh5lLIqbcEl1Crb9QGQcgb5AYLqOhT7MNhBdVmJLpbLAw0G_bBpgzpwg0rW2eZp8ahVXYRn435WfPv44evyYnZ59Wm1PL-caV6TNDO6JQCYYCix4QBQQSuEqbTSdP8oWUtqwxnD0ELLqGG4qSlfgCZ0YURNz4qXB99d56Mcg4uSMEHKhaCUZ2J1IIxX13IX7FaFW-mVlX8OfFhLFZLVHUioal7RGkwrKiYa3bQVEKMrQxuDBTbZ6_34tb7ZgtE5pBzKxHT6xtmNXPtBClHlv0KywavRIPibHmL6x5VHaq3yraxrfTbTWxu1POeMEy4qwjI1_wuVl4Gt1bk6rc3nE8GbiSAzCX6mtepjlKsvn_-fvfo-ZV8fsRtQXdpE3_XJehenIDuAOvgYA7T3yeFS7pt_l4bcN1-Ozc-yF8ep34vuqk5_AzzcAV4</recordid><startdate>20201222</startdate><enddate>20201222</enddate><creator>Hayashi, Tsuguru</creator><creator>Shibata, Michihiko</creator><creator>Oe, Shinji</creator><creator>Miyagawa, Koichiro</creator><creator>Honma, Yuichi</creator><creator>Harada, Masaru</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-3312-1672</orcidid></search><sort><creationdate>20201222</creationdate><title>C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib</title><author>Hayashi, Tsuguru ; Shibata, Michihiko ; Oe, Shinji ; Miyagawa, Koichiro ; Honma, Yuichi ; Harada, Masaru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-dcf2ee121e01d6eee5ef77d5cac35cac04f29d6441efef43d41b9368ec238d793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Ablation</topic><topic>Aged</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biology and Life Sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>C-reactive protein</topic><topic>C-Reactive Protein - metabolism</topic><topic>Cancer therapies</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - metabolism</topic><topic>Confidence intervals</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Environmental health</topic><topic>Female</topic><topic>Hepatocellular carcinoma</topic><topic>Hepatoma</topic><topic>Humans</topic><topic>Internal medicine</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - metabolism</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical records</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Multivariate Analysis</topic><topic>Patient outcomes</topic><topic>Phenylurea Compounds - administration & dosage</topic><topic>Phenylurea Compounds - therapeutic use</topic><topic>Physical Sciences</topic><topic>Physiological aspects</topic><topic>Proteins</topic><topic>Quinolines - administration & dosage</topic><topic>Quinolines - therapeutic use</topic><topic>Research and Analysis Methods</topic><topic>Retrospective Studies</topic><topic>Survival</topic><topic>Survival Analysis</topic><topic>Time-to-Treatment</topic><topic>Treatment Failure</topic><topic>Treatment resistance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hayashi, Tsuguru</creatorcontrib><creatorcontrib>Shibata, Michihiko</creatorcontrib><creatorcontrib>Oe, Shinji</creatorcontrib><creatorcontrib>Miyagawa, Koichiro</creatorcontrib><creatorcontrib>Honma, Yuichi</creatorcontrib><creatorcontrib>Harada, Masaru</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hayashi, Tsuguru</au><au>Shibata, Michihiko</au><au>Oe, Shinji</au><au>Miyagawa, Koichiro</au><au>Honma, Yuichi</au><au>Harada, Masaru</au><au>Huang, Yi-Hsiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2020-12-22</date><risdate>2020</risdate><volume>15</volume><issue>12</issue><spage>e0244370</spage><pages>e0244370-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Lenvatinib has become a first line treatment for unresectable hepatocellular carcinoma (HCC). However, continued administration is impossible in many patients due to treatment resistance and severe adverse events. This study aimed to identify predicting factors to select patients likely to benefit from lenvatinib treatment.
We retrospectively analyzed 53 patients who were treated with lenvatinib for unresectable HCC. They were divided to two groups; low C-reactive protein (CRP) group with pretreatment serum CRP level < 1.0 mg/dL and high CRP group with serum CRP level ≥ 1.0 mg/dl. Overall survival (OS), total amount administered, and period of treatment were compared between the two groups.
The high CRP group showed a significantly poorer OS than the low CRP group (0.0% vs 71.5%/ 1year, p < 0.01). Multivariate analyses revealed that high CRP was a significant negative factor for OS (HR: 7.69, 95% confidence interval: 2.43-24.3, p < 0.001), and this result was independent of Child-Pugh score and existing tumor factors. Relative dose intensity at 8 weeks was lower (p = 0.01) and time to treatment failure was shorter (P < 0.001) in the high CRP group.
CRP level was associated with OS in HCC patients treated with lenvatinib. CRP could be a useful marker to identify patients most likely to benefit from lenvatinib treatment.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>33351844</pmid><doi>10.1371/journal.pone.0244370</doi><tpages>e0244370</tpages><orcidid>https://orcid.org/0000-0002-3312-1672</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2020-12, Vol.15 (12), p.e0244370 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_pubmed_primary_33351844 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Public Library of Science (PLoS); PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Ablation Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Biology and Life Sciences Biomarkers, Tumor - blood C-reactive protein C-Reactive Protein - metabolism Cancer therapies Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - metabolism Confidence intervals Drug dosages Drug therapy Environmental health Female Hepatocellular carcinoma Hepatoma Humans Internal medicine Liver cancer Liver Neoplasms - drug therapy Liver Neoplasms - metabolism Male Medical prognosis Medical records Medicine Medicine and Health Sciences Multivariate Analysis Patient outcomes Phenylurea Compounds - administration & dosage Phenylurea Compounds - therapeutic use Physical Sciences Physiological aspects Proteins Quinolines - administration & dosage Quinolines - therapeutic use Research and Analysis Methods Retrospective Studies Survival Survival Analysis Time-to-Treatment Treatment Failure Treatment resistance |
| title | C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T04%3A51%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=C-reactive%20protein%20can%20predict%20dose%20intensity,%20time%20to%20treatment%20failure%20and%20overall%20survival%20in%20HCC%20treated%20with%20lenvatinib&rft.jtitle=PloS%20one&rft.au=Hayashi,%20Tsuguru&rft.date=2020-12-22&rft.volume=15&rft.issue=12&rft.spage=e0244370&rft.pages=e0244370-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0244370&rft_dat=%3Cgale_plos_%3EA646267524%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2472087336&rft_id=info:pmid/33351844&rft_galeid=A646267524&rft_doaj_id=oai_doaj_org_article_e596539edf7547bcbf5e2dc5d3bd171d&rfr_iscdi=true |